Schizophrenia and co-morbidity risk: Evidence from a data driven phenomewide association study.

Journal: Journal of psychiatric research

Volume: 162

Issue: 

Year of Publication: 2023

Affiliated Institutions:  Australian Centre for Precision Health, University of South Australia, Adelaide, Australia; Department of Pharmacology, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. Australian Centre for Precision Health, University of South Australia, Adelaide, Australia; Clinical and Health Sciences, University of South Australia, Adelaide, Australia. Electronic address: vijay.suppiah@unisa.edu.au. Australian Centre for Precision Health, University of South Australia, Adelaide, Australia; Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK; South Australian Health and Medical Research Institute, Adelaide, Australia.

Abstract summary 

Schizophrenia is a chronic debilitating psychiatric disorder with significant morbidity and mortality. In this study, we used information from 337,484 UK Biobank participants and performed PheWAS using schizophrenia genetic risk score on 1135 disease outcomes. Signals that passed the false discovery rate threshold were further analyzed for evidence on the causality of the association. We extended the analysis to 30 serum, four urine, and six neuroimaging biomarkers to identify biomarkers that could be affected by schizophrenia. Schizophrenia GRS was associated with 54 (39 distinct) disease outcomes including schizophrenia in the PheWAS analysis. Of these, a causal association were found with 10 distinct diseases in the MR analysis. Schizophrenia causally linked with higher odds of anxiety (OR = 1.41, 95%CI 1.12 to 1.21), bipolar disorder (OR = 1.52, 95%CI 1.36 to 1.70), major depressive disorder (OR = 1.12, 95%CI 1.08 to 1.16) and suicidal ideation (OR = 1.30, 95%CI 1.19 to 1.42). Lower odds were found for several diseases including type 1 diabetes, coronary atherosclerosis and some musculoskeletal disorders. In analyses using biomarkers, schizophrenia was associated with lower serum 25(OH)D, gamma glutamyltransferase, cystatin C, serum creatinine. However, we did not find association with any of the brain imaging markers. Our analyses confirmed the co-existence of schizophrenia with other mental health disorders but did not otherwise suggest strong effects on disease risk. Biomarker analyses reflected associations which could be explained by unhealthy lifestyles, suggesting patients with schizophrenia may benefit from screening for and managing broader health aspects.

Authors & Co-authors:  Mulugeta Anwar A Suppiah Vijayaprakash V Hyppönen Elina E

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  3
Identifiers
Doi : 10.1016/j.jpsychires.2023.04.010
SSN : 1879-1379
Study Population
Male,Female
Mesh Terms
Humans
Other Terms
Causal effects;MR;Mendelian randomization;PheWAS;Phenome-wide;Schizophrenia
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
England